Oramed Pharmaceuticals (ORMP) Retained Earnings (2011 - 2026)

Oramed Pharmaceuticals has reported Retained Earnings for 16 years, with the latest figure at -$85.1 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 53.8% year-over-year to -$85.1 million; the trailing twelve-month figure through Mar 2026 stood at -$85.1 million (up 53.8% YoY), and the FY2025 full-year result was -$123.4 million, up 30.11% from the prior year.
• Retained Earnings for Q1 2026 stood at -$85.1 million, up from -$123.4 million in the prior quarter.
• The five-year high for Retained Earnings was -$85.1 million in Q1 2026, with the low at -$184.3 million in Q1 2025.
• Historically, Retained Earnings has averaged -$152.8 million across 5 years, with a median of -$157.6 million in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings dropped 21.56% — and 2026, when it jumped 53.8%.
• Oramed Pharmaceuticals' Retained Earnings stood at -$163.1 million in 2022, then advanced by 3.39% to -$157.6 million in 2023, then declined by 12.1% to -$176.6 million in 2024, then soared by 30.11% to -$123.4 million in 2025, then soared by 31.04% to -$85.1 million in 2026.
• The last three Retained Earnings figures came in at -$85.1 million (Q1 2026), -$123.4 million (Q4 2025), and -$122.6 million (Q3 2025), per Business Quant data.